Medium-term plans, capital spending, new plants, products and drug approvals from Japanese companies.
Shionogi and Torii Pharmaceutical secured Japanese approval to prescribe a 0.5% version of their non-steroid eczema cream to children under 12, backed by a trial in patients aged 2 to under 12 showing it beat plain vehicle cream over eight weeks with good long-term tolerability.
Eisai's newly approved subcutaneous Leqembi pen lets patients self-inject weekly at home instead of visiting a clinic every two weeks for IV infusion, but a Central Social Insurance Medical Council review and listing on the injectable drug list must happen first, and Eisai says the approval's effect on its coming-year earnings forecast is minor.
METI has certified Central Glass's plan to build new anhydrous hydrofluoric acid capacity at its Ube plant, unlocking as much as ¥17.6bn in subsidy under Japan's economic-security law, though the company says investment details and the near-term earnings impact remain modest.
The plastics-machinery maker disputes a newspaper report blaming weak demand for its frozen Saku, Nagano factory plan, saying construction-cost inflation and labor shortages forced the retreat while it keeps expanding capacity in India.
Daiseki's environmental subsidiary has secured a ¥2.92bn government subsidy toward a ¥9.95bn plastic-resource recycling plant in Shizuoka, conditioned on lifting per-employee pay on the project by 10.4%, with the resulting special profit not booked until the year to February 2030 and the final subsidy figure still subject to a post-completion review.
The Tokyo-listed colorant and pigment maker will stop offset-ink production in Sapporo by December 2026 and close the site by March 2027, while its Osaka colorant plant runs until September 2028 ahead of a March 2029 closure, as it exits businesses that made up about 5% of last year's group sales to fund a push toward IT, electronics and mobility materials.
GO Inc. and Alphabet's Waymo have signed a deal to move from supervised test rides to a driverless taxi service in Tokyo, aiming to launch Japan's first Level 4 commercial robotaxi operation in 2027.
AEON Fantasy's board has ordered the dissolution of its Beijing children's-amusement subsidiary, which had run up negative net worth of about 810 million yuan after years of pandemic-hit, competition-squeezed losses, and the company is first converting ¥19.4bn of loan claims into equity and injecting ¥4.3bn more capital before the wind-down completes around the year ending February 2028.
Terra Drone was the only company among 38 applicants to pass Japan's first interceptor-drone demonstration and sign a mass-production contract with the country's defense procurement agency, a milestone disclosed alongside a widened first-half operating loss of ¥819mn and a new Tokyo-based subsidiary built to run the defense business.
The FDA has accepted Takeda's application for zasocitinib, a once-daily pill for moderate-to-severe plaque psoriasis, for priority review, with a decision due in the first quarter of 2027; across two phase 3 trials roughly 70% of patients reached clear or almost-clear skin by 16 weeks, well ahead of both placebo and the comparator drug apremilast, though Takeda says the filing itself does not change its earnings outlook for the year to March 2027.
Zipalertinib plus chemotherapy nearly doubled progression-free survival to 14.5 months against a hard-to-treat EGFR mutation in a Phase 3 readout, but the drug is approved nowhere and Otsuka is leaving its current profit forecast untouched.
Shikoku Electric Power Transmission & Distribution will lift wheeling charges across every voltage class from November 1, adding a net ¥33.8bn to projected revenue over two years, but the parent utility still has not decided how much of that increase reaches retail electricity bills.
Kansai Transmission and Distribution's METI filing raises wheeling tariffs at every voltage level from November 1, with low-voltage connections taking the biggest hit, up ¥1.22 to ¥9.04 per kWh, a cost retail electricity suppliers pay before any pass-through to customer bills is decided.
JACCS is closing four regional credit-screening offices and cutting its network from 11 sites to seven, offering the 180 affected employees a transfer, a relocation-based role change or a payout that could total up to ¥1.1bn in severance if everyone chooses to leave by March 2027.
Astroscale France will earn €13.2mn, about ¥2.36bn, through 2030 as subcontractor to Exotrail on a CNES-backed mission to deorbit a Eutelsat OneWeb satellite, the unit's first paying contract.
Seikagaku's Complete Response Letter from the FDA flags unresolved deficiencies at its active-ingredient plant and new problems at a contract formulator for SI-6603, with no concerns raised about the drug's efficacy or safety data and no resubmission date given.
Quantum Solutions has handed over US$8.3mn, 13.6% of a US$61mn GPU-server contract, funded by a dilutive share allotment and crypto-asset sales, and now says its unnamed Kanto-based supplier's earlier 'in stock' claim referred to procurement capacity rather than all the servers already sitting in inventory.
Redasemtid, StemRIM's HMGB1-peptide drug licensed to Shionogi, missed its primary endpoint in a global stroke trial's no-reperfusion cohort, while a small four-patient trial in the rare skin disease dystrophic epidermolysis bullosa hit its mark with three ulcer closures; Shionogi now decides the stroke program's future.
Quantum Solutions never signed a contract or paid a yen to Rubin Tech Inc. for its planned GPU servers; it has now committed $60.99mn to an unnamed Kanto vendor to nearly quadruple its server count for an Osaka AI data center, funded partly by a $2.6mn loan from a Hong Kong shareholder that will not disclose its own finances.
pluszero says its miraio phone-answering AI is live at four companies, including a securities brokerage, with seven more still in preparation, as nine-month operating profit rose 29% to ¥509mn.
Meiji Holdings' new Shanghai dairy-sales subsidiary, capitalized above 650 million yuan and wholly owned indirectly, crossed the size threshold that forces disclosure under Japan's securities law.
FLIGHT SOLUTIONS says a repeat customer's new order for its Incredist Trinity Mini is worth at least 10% of last year's revenue; the exact price is confidential under an agreement with the buyer, and the company says the deal is already baked into its existing guidance.
Japan Engine Corporation's 6UEC35LSGH hit a hydrogen co-firing ratio above 95% and cut emissions by the same margin against heavy-oil engines in factory tests witnessed by ClassNK, but the engine still has to survive installation on a Mitsui O.S.K. Lines vessel and at-sea demonstration testing from April 2028 before it counts as proven.
Japan Engine Corporation's 6UEC35LSGH cut emissions by 95% or more against a heavy-fuel-oil engine in factory trials, but the real test, an April 2028 sea demonstration aboard a Mitsui O.S.K. Lines vessel, is still nearly two years off.